Hormonal IUD (Mirena/Kyleena) and Relationships: What to Expect for Your Intimacy and Daily Life

How a Hormonal IUD Actually Changes Your Sex Life

Most women who switch to a levonorgestrel IUD do not experience a meaningful drop in sexual desire or satisfaction. The largest prospective study to ask this question directly, the CHOICE Project, enrolled more than 9,000 women across contraceptive methods and found that IUD users reported higher 12-month continuation and satisfaction rates than pill users, driven largely by the removal of contraceptive burden from the sexual encounter itself.

The logic is straightforward. When you no longer have to remember a daily pill, worry about a missed dose before sex, or manage unpredictable bleeding, sex becomes lower-stakes. That reduction in anticipatory anxiety matters.

The Libido Question: What the Data Actually Shows

Libido is not one thing. It has desire, arousal, lubrication, orgasm, and satisfaction components, each measured separately in validated tools like the Female Sexual Function Index (FSFI). A 2019 prospective cohort published in the European Journal of Contraception and Reproductive Health Care followed women for 12 months after Mirena insertion and found no statistically significant change in FSFI total score compared to baseline, though individual subscale scores for desire did dip slightly in the first three months before stabilizing.

That three-month window is worth naming. Insertion cramping, irregular spotting, and the general adjustment period can suppress desire temporarily. Women who are told to expect this are less likely to attribute it to a permanent drug effect.

When Libido Does Drop

A minority of women, roughly 6 to 8 percent in post-marketing surveillance data, report decreased libido listed among device-related adverse events. Risk factors appear to include a personal or family history of depression, significant PMS or PMDD before insertion, and high baseline anxiety. If you fall into any of those categories, discuss this honestly with your prescriber before insertion, not after.

Androgenic activity is relevant here. Levonorgestrel has mild androgenic receptor affinity, which in theory could support libido, but plasma levels from an IUD are low enough that this is unlikely to be clinically meaningful in most women. The pill, by contrast, raises sex-hormone-binding globulin and can suppress free testosterone more substantially, which is one reason some women actually notice an improvement in desire when they switch from the pill to an IUD.

Strings, Physical Comfort, and What Your Partner Notices

The polyethylene strings that hang through the cervix are a practical reality of IUD use. They soften over time as they absorb cervical fluid and curl around the cervix. Approximately 29% of male partners report feeling IUD strings during intercourse, according to a survey of 202 couples published in Contraception. The sensation is usually described as a minor scratching feeling rather than pain.

Trimming and Positioning

Your clinician can trim strings shorter at any follow-up visit. Shorter strings are less likely to be felt but harder to check for correct placement, so there is a real trade-off. Some positions (deep penetration from behind) make string contact more likely. Changing angles often resolves the problem without any clinical intervention.

Pain During Intercourse After Insertion

Dyspareunia in the first four to six weeks post-insertion is common and usually reflects uterine cramping rather than structural injury. A 2021 review in the American Journal of Obstetrics and Gynecology noted that women with smaller uteri, nulliparous women, and women with adenomyosis are more likely to report persistent pelvic discomfort after IUD insertion. If pain with sex persists beyond eight weeks, an ultrasound to confirm correct placement is appropriate.

For Same-Sex and Non-Penetrative Partnerships

String awareness is specific to vaginal penetration. For women in relationships that do not involve penile-vaginal intercourse, strings are not a physical concern for partners, though they remain something you may notice when using menstrual cups or during internal examination.

Mood, Mental Health, and the Relationship Beneath the Surface

Mood changes affect relationships in ways that are harder to study than strings. The data here is genuinely mixed, and honesty matters.

What Prospective Studies Show

A large Danish register study published in JAMA Psychiatry in 2016 followed 1.06 million women aged 15 to 34 and found that hormonal contraceptive users had higher rates of first antidepressant prescription and first depression diagnosis than non-users. For the levonorgestrel IUD specifically, the adjusted relative risk for first antidepressant use was 1.44 compared to non-users. The study was observational and cannot prove causation, but it is the most cited data point in this conversation and you deserve to know it.

Counterpoint: the same age group has high baseline rates of new depression diagnoses regardless of contraceptive use, and women who are not using contraception may have different baseline health profiles.

Progestin Sensitivity Is Real

Some women are genuinely progestin-sensitive, meaning they experience mood, sleep, or anxiety changes with even low systemic progestin exposure. This appears to be linked to neurosteroid pathways, specifically how allopregnanolone (a progesterone metabolite) interacts with GABA-A receptors. Women with a history of premenstrual dysphoric disorder show altered GABA-A receptor sensitivity, which may explain why a subset of IUD users notice mood effects even at the low plasma levels delivered by a local device.

The WomanRx Progestin-Sensitivity Screen: Before insertion, ask yourself four questions. Do you have a diagnosed history of PMDD or severe PMS? Did you experience significant mood changes on any hormonal contraceptive before? Do you have a personal history of major depressive disorder? Did a prior progestin-containing method cause you to stop using it? Two or more "yes" answers suggest you and your clinician should discuss a copper IUD as an alternative, or agree on a clear mood-monitoring plan with a 3-month check-in appointment already scheduled.

Talking to Your Partner About Mood Changes

The relationship impact of mood changes is disproportionate to the symptom intensity. A mild increase in irritability or emotional lability, if unexplained to a partner, can be misread as relationship dissatisfaction. Naming what is happening, "I'm in my adjustment period with the new IUD and my mood may be variable for a few months," gives partners context and reduces interpersonal friction.

Life-Stage Differences: Reproductive Years, Perimenopause, and Beyond

Reproductive Years and Women Trying to Conceive (Not Yet)

For women in their 20s and 30s who are actively avoiding pregnancy but plan to conceive in the future, fertility return after removal is prompt. Median time to ovulation after Mirena removal is approximately 30 days, and pregnancy rates in the year after removal are comparable to women who used barrier methods. This is worth knowing because relationship conversations about "when" often involve contraception timelines.

PCOS

Women with polycystic ovary syndrome often have heavier, more irregular cycles and elevated androgens. The LNG-IUD reduces menstrual bleeding substantially, which is a quality-of-life benefit independent of contraception. There is no evidence that the IUD worsens androgen-related symptoms, and the low systemic LNG exposure means it does not affect the hypothalamic-pituitary-ovarian axis in a way that further disrupts ovulation (since ovulation may already be irregular in PCOS). Sexual quality of life in women with PCOS who have the IUD has not been studied in an adequately powered RCT. This is an evidence gap worth naming.

Endometriosis

Endometriosis causes dyspareunia (pain with sex) that can devastate intimate relationships. The Mirena IUD is used off-label and in some guidelines as a maintenance therapy post-excision surgery. A 2019 Cochrane review found that the LNG-IUD reduced endometriosis-associated pelvic pain compared to expectant management. Reducing pain with intercourse directly improves sexual function. Women with endometriosis using Mirena for pain management should track both pain scores and FSFI subscales at 3 and 6 months to assess response.

Perimenopause

This is an underappreciated use case. Perimenopausal women often have erratic, heavy cycles that strain daily life and relationships. The ACOG Practice Bulletin on abnormal uterine bleeding recognizes the LNG-IUD as first-line management for heavy menstrual bleeding. Beyond bleeding, the Mirena IUD serves as the progestogen component of menopausal hormone therapy (MHT) in women who have a uterus and want estrogen, protecting the endometrium while avoiding systemic progestin side effects. The British Menopause Society supports this use. For perimenopausal women, the IUD may actually improve intimacy by eliminating flooding, reducing dysmenorrhea, and allowing estrogen therapy (via patch or gel) to be used without the mood-disrupting effects of oral progestogens.

Postmenopause

The Mirena IUD is not indicated as a standalone treatment in postmenopausal women and is typically removed at menopause if no longer needed for endometrial protection within an MHT regimen. Strings may be harder to locate as the cervix atrophies, so removal should be done while the device is still within its approved duration.

Pregnancy, Lactation, and Contraception: The Required Conversation

The levonorgestrel IUD is contraindicated in confirmed pregnancy. This is not a conditional statement.

If You Become Pregnant with an IUD In Situ

The failure rate of the 52 mg LNG-IUD is approximately 0.1 to 0.2 per 100 women-years, making it one of the most effective reversible contraceptives available. However, if pregnancy does occur with an IUD in place, the risk of ectopic pregnancy is elevated. Any positive pregnancy test with an IUD in situ requires urgent evaluation to rule out ectopic implantation. If the IUD strings are visible, guidelines recommend removal of the device because leaving it in place is associated with significantly higher rates of miscarriage, preterm birth, and chorioamnionitis. ACOG advises removal when strings are accessible and the patient wishes to continue the pregnancy.

Lactation Safety

Levonorgestrel is excreted in breast milk in small amounts. A WHO Medical Eligibility Criteria for Contraceptive Use (MEC) category 2 classification applies to LNG-IUD use in women who are less than 6 weeks postpartum. From 6 weeks onward, it is MEC category 1, meaning no restriction. Infant exposure to LNG via milk is estimated at less than 0.1% of the maternal weight-adjusted dose and has not been associated with adverse infant effects in available studies. For most breastfeeding women, the LNG-IUD is the preferred hormonal contraceptive because it does not suppress milk supply the way combined estrogen-progestin methods can.

Postpartum Insertion Timing

The IUD may be inserted immediately postpartum (within 10 minutes of placental delivery) or at 4 to 6 weeks postpartum. ACOG supports immediate postpartum insertion to reduce unintended pregnancy risk, acknowledging a slightly higher expulsion rate (roughly 24% at 6 months) compared to interval insertion. This is a relevant relationship and life-planning consideration for women navigating postpartum intimacy.

Who This Is Right For, and Who Should Think Twice

Likely to Benefit Most

Women who report that contraceptive burden (remembering pills, navigating condom negotiations, tracking cycles) has been a source of relationship stress. Women with heavy, painful periods that limit sexual frequency. Women with endometriosis using it post-surgically for pain maintenance. Perimenopausal women seeking bleeding control who also want to use transdermal estrogen. Breastfeeding women who need effective contraception without affecting milk supply.

Consider Alternatives or Monitor Closely

Women with a documented history of PMDD or progestin-intolerance on prior methods. Women with a current, untreated depressive episode. Women with a very small uterine cavity (Kyleena, with its smaller frame at 28 mm versus Mirena's 32 mm, may be better tolerated in nulliparous women or those with a smaller uterus). Women with current cervicitis or PID, unexplained vaginal bleeding, or uterine abnormalities that distort the cavity. Women who are pregnant or may be pregnant: the device must not be inserted.

Daily Life Beyond the Bedroom

Relationship impact is only part of the daily-life picture. Women ask about exercise, travel, and routine.

Exercise and Sport

There is no exercise restriction after the first 24 to 48 hours post-insertion. Women who participate in high-impact sports, cycling, or horseback riding do not have higher rates of IUD displacement. Menstrual cup use is compatible with an IUD when strings are trimmed appropriately and insertion is careful, though some clinicians prefer tampon use until confirmed by ultrasound that strings are not at risk of being dislodged.

Travel and Access to Care

One underappreciated lifestyle advantage: once the IUD is in place, you do not need pharmacy access, refrigeration, or a daily routine to maintain contraceptive protection. For women who travel internationally for work or who live in areas with limited pharmacy access, this matters.

Checking Your Strings

You can check your own strings monthly after your period (or at a consistent interval if you have amenorrhea). Insert a clean finger into the vagina and feel for the thin monofilament threads at the cervix. You should feel the strings but not the hard plastic of the device itself. If strings feel longer, shorter, or absent, or if you feel the hard device, contact your clinician. This routine takes under 30 seconds and gives you ongoing assurance that the device is in place.

What Happens When You Decide to Remove It

Removal is a one-appointment procedure. A clinician grasps the strings with forceps and applies gentle traction. It takes seconds and is typically less painful than insertion. Fertility, as noted above, returns within one to two ovulatory cycles for most women. If mood changes or libido shifts occurred on the IUD, most women report symptom resolution within one to three months after removal, though formal studies tracking this timeline are sparse. This is an evidence gap the field needs to address.